Sponsrat Sponsrat

OssDsign’s CFO Claes Lindblad is leaving the company

OssDsign AB (publ) today announces that CFO Claes Lindblad is leaving the company in order to pursue other opportunities.

Uppdaterad 2020-11-13
Publicerad 2020-11-13

A leading international recruitment firm has been engaged to lead the search process for a new CFO. Anders Svensson, a highly experienced leader with international experience, will take up the position as interim CFO as of Monday November 16, 2020. Anders Svensson has previous experience from amongst other Aura Light and Bluefish Pharmaceuticals.

"I am very happy to welcome Anders Svensson as interim CFO. Anders, with his solid experience, will contribute to our efforts to integrate Sirakoss as well as to the company’s continued development. I also want to thank Claes Lindblad for his contributions and commitment", says Morten Henneveld, CEO.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.